

# Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline

Jeanne Carter, Christina Lacchetti, Barbara L. Andersen, Debra L. Barton, Sage Bolte, Shari Damast, Michael A. Diefenbach, Katherine DuHamel, Judith Florendo, Patricia A. Ganz, Shari Goldfarb, Sigrun Hallmeyer, David M. Kushner, and Julia H. Rowland

Author affiliations and support information (if applicable) appear at the end of this article.

Published at [jco.org](http://jco.org) on December 11, 2017.

J.C. and J.H.R. were Expert Panel co-chairs.

Clinical Practice Guideline Committee approved: August 24, 2017.

Editor's note: This American Society of Clinical Oncology Clinical Practice Guideline provides recommendations, with comprehensive review and analyses of the relevant literature for each recommendation. Additional information, including a Data Supplement with additional evidence tables, a Methodology Supplement, slide sets, clinical tools and resources, and links to patient information at [www.cancer.net](http://www.cancer.net), is available at [www.asco.org/survivorship-guidelines](http://www.asco.org/survivorship-guidelines) and [www.asco.org/guidelineswiki](http://www.asco.org/guidelineswiki).

Reprint requests: American Society of Clinical Oncology, 2318 Mill Rd, Suite 800, Alexandria, VA 22314; [guidelines@asco.org](mailto:guidelines@asco.org)

Corresponding author: American Society of Clinical Oncology, 2318 Mill Rd, Suite 800, Alexandria, VA 22314; e-mail: [guidelines@asco.org](mailto:guidelines@asco.org).

© 2017 by American Society of Clinical Oncology

0732-183X/18/3605w-492w/\$20.00

## A B S T R A C T

### Purpose

The adaptation of the Cancer Care Ontario (CCO) guideline Interventions to Address Sexual Problems in People With Cancer provides recommendations to manage sexual function adverse effects that occur as a result of cancer diagnosis and/or treatment.

### Methods

ASCO staff reviewed the guideline for developmental rigor and updated the literature search. An ASCO Expert Panel (Table A1) was assembled to review the guideline content and recommendations.

### Results

The ASCO Expert Panel determined that the recommendations from the 2016 CCO guideline are clear, thorough, and based upon the most relevant scientific evidence. ASCO statements and modifications were added to adapt the CCO guideline for a broader audience.

### Recommendations

It is recommended that there be a discussion with the patient, initiated by a member of the health care team, regarding sexual health and dysfunction resulting from cancer or its treatment. Psychosocial and/or psychosexual counseling should be offered to all patients with cancer, aiming to improve sexual response, body image, intimacy and relationship issues, and overall sexual functioning and satisfaction. Medical and treatable contributing factors should be identified and addressed first. In women with symptoms of vaginal and/or vulvar atrophy, lubricants in addition to vaginal moisturizers may be tried as a first option. Low-dose vaginal estrogen, lidocaine, and dehydroepiandrosterone may also be considered in some cases. In men, medication such as phosphodiesterase type 5 inhibitors may be beneficial, and surgery remains an option for those with symptoms or treatment complications refractory to medical management. Both women and men experiencing vasomotor symptoms should be offered interventions for symptomatic improvement, including behavioral options such as cognitive behavioral therapy, slow breathing and hypnosis, and medications such as venlafaxine and gabapentin. Additional information is available at: [www.asco.org/survivorship-guidelines](http://www.asco.org/survivorship-guidelines) and [www.asco.org/guidelineswiki](http://www.asco.org/guidelineswiki).

*J Clin Oncol* 36:492-511. © 2017 by American Society of Clinical Oncology

## INTRODUCTION

Extraordinary advances in cancer diagnosis and treatment have led to more than 16.5 million people living with and beyond cancer in the United States.<sup>1</sup> Modern multimodality treatment, including surgery, radiotherapy, systemic chemotherapy, and targeted therapy, can result in short-term and long-term adverse physical and/or

psychosocial effects. Although prevalence rates of sexual difficulties associated with cancer and its treatment vary depending on primary diagnosis, treatment modality, methods of assessment, and type of sexual difficulty,<sup>2</sup> estimates are reported to range from 40% to 100%.<sup>3,4</sup> This includes disorders of sexual desire and sexual response influenced by the biologic, physiologic, and psychological challenges that cancer and its treatments present.

### ASSOCIATED CONTENT

Appendix  
DOI: <https://doi.org/10.1200/JCO.2017.75.8995>

Data Supplement  
DOI: <https://doi.org/10.1200/JCO.2017.75.8995>

DOI: <https://doi.org/10.1200/JCO.2017.75.8995>

## THE BOTTOM LINE

**Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline****Guideline Question**

What is the effectiveness of pharmacological interventions, psychosocial counseling, or devices to manage sexual problems after cancer treatment? More specifically, issues in men and in women were examined separately.

**Target Population**

This guideline is applicable to adult ( $\geq 18$  years of age) men and women (and their partners) of all sexual orientations living with cancer of any type. For the purposes of this guideline, men and women who were previously treated for a childhood cancer were not included.

**Target Audience**

Health care practitioners, such as oncologists, urologists, gynecologists, primary care providers, surgeons, nurses, physiotherapists, social workers, counselors, psychologists, psychiatrists, and sex therapists/counselors, and advanced practice providers, such as physician assistants and nurse practitioners.

**ASCO Recommendations for Interventions to Address Sexual Problems in People With Cancer**

The ASCO Expert Panel's modifications to Cancer Care Ontario's (CCO's) recommendations and qualifying statements appear in **bold italics**. ASCO's own qualifying statements appear in *italics*. A list of the original CCO recommendations can be found in [Table 1](#).

**For All People With Cancer**

**Recommendation 1.** It is recommended that there be a discussion with the patient, initiated by a member of the health care team, regarding sexual health and dysfunction resulting from the cancer or its treatment. The conversation **could** include the patient's partner, **only if the patient so wishes**. This issue should be raised with the individual at the time of diagnosis and continue to be reassessed periodically throughout follow-up. The Expert Panel believes that this is a vital recommendation. The recommendations that follow cannot be used unless someone has taken the initiative to ask.

It is recommended that there be access to resources or referral information for the patient (and partner).

*ASCO Qualifying Statement.* The Expert Panel believes that introduction of the topic of sexual function should be held with the patient alone, with the option of later partner inclusion if desired by the patient. Discussions should be congruent with the patient's literacy level, cultural/religious beliefs, and sexual orientation. This discussion should be offered at varied points of treatment and survivorship to assess or address any changes.

**For Women With Cancer****CONDITION: SEXUAL RESPONSE**

**Recommendation 1.** The Expert Panel believes that psychosocial **and/or psychosexual** counseling should be offered to women with cancer, aiming to improve elements of sexual response such as desire, arousal, or orgasm. Current evidence does not support one type of psychosocial **or psychosexual** counseling to be superior to another.

**Clinicians may offer flibanserin to premenopausal women who are experiencing hypoactive sexual desire disorder.** <sup>14,15</sup>

*CCO Qualifying Statement.* It is the opinion of the Expert Panel that any kind of regular stimulation (including masturbation) would likely be of benefit for improving sexual response, regardless of the stimulation used.

*ASCO Qualifying Statement.* It should be noted that flibanserin has not been evaluated in women with a history of cancer or those on endocrine therapy. In addition, the risk/benefit ratio for this medication is uncertain.

**CONDITION: BODY IMAGE**

**Recommendation 2.** It is recommended that psychosocial counseling be offered to women with cancer and body image issues.

If a woman is partnered, evidence indicates that couples-based interventions are effective when compared with usual care.

(continued on following page)

## THE BOTTOM LINE (CONTINUED)

No recommendation can be made for or against group therapy (with or without exercise) for women with body image issues.

*ASCO Qualifying Statement. Clinicians should assess for body image issues early and often in the cancer care continuum and should take into account cultural and/or religious variations. Patients with preexisting depression and/or body image issues may be at a higher risk of susceptibility.*

### **CONDITION: INTIMACY/RELATIONSHIPS**

*Recommendation 3. It is recommended that psychosocial counseling be offered to women with cancer aiming to improve intimacy and relationship issues. If a woman is partnered, evidence indicates that couples-based interventions are effective when compared with usual care.*

*ASCO Qualifying Statement. The Expert Panel views partner involvement in all cases to be the choice of the patient.*

### **CONDITION: OVERALL SEXUAL FUNCTIONING AND SATISFACTION**

*Recommendation 4. The Expert Panel believes that psychosocial counseling directed at the individual or couple or delivered in a group be offered to women with cancer who have problems with overall sexual functioning. Physical exercise or pelvic floor physiotherapy, in addition to psychosocial counseling, may also be of benefit.*

Current evidence does not support a specific psychosocial counseling intervention to improve sexual functioning and satisfaction.

***Health care providers should screen patients with cancer for overall sexual functioning and satisfaction, and a diagnosis should be established when there are physical issues playing a contributing role.***

***All patients should be offered education and symptom management based on the patient's diagnosis. For patients having persistent concerns, such as physical issues, a gynecologic examination would be ideal. For those continuing to have relationship issues and/or distress, mental health counseling should be an option.***

*ASCO Qualifying Statement. The ASCO Expert Panel believes patients can still benefit if counseling is provided by licensed counselors available at the medical center even if specialized therapists (eg, sex therapists) are not available.*

### **CONDITION: VASOMOTOR SYMPTOMS**

*Recommendation 5. For women with vasomotor symptoms, hormone therapy is the most effective intervention. For women unwilling or unable to use hormonal therapy, alternatives exist: for example, paroxetine, venlafaxine, gabapentin, or clonidine.*

Having a hormone-sensitive breast cancer is a contraindication to using systemic hormone therapy.

Psychosocial counseling (cognitive behavioral therapy) **and/or clinical hypnosis** may provide a benefit and reduce vasomotor symptoms and should be offered.<sup>16-19</sup>

*CCO Qualifying Statement. The Expert Panel emphasizes that women with non-hormone-sensitive cancers who develop vasomotor symptoms from their cancer treatment should be counseled to consider hormone therapy until the average age of menopause, approximately 51 years, at which point they should be re-evaluated. Risks typically cited for hormone therapy are derived from studies of postmenopausal women. Beyond the age of 51 years, hormone therapy is an individual therapy with few risks for symptomatic patients in their 50s. It should be intermittently evaluated for long-term use.*

When not contraindicated, estrogen therapy alone (oral, transdermal, or vaginal) is recommended for women who have had a hysterectomy, as it has a more beneficial risk/benefit profile.

Paroxetine and fluoxetine should not be offered to women with breast cancer taking tamoxifen. Adverse events of clonidine include hypotension, light-headedness, headache, dry mouth, dizziness, sedation, and constipation. Sudden cessation can lead to significant elevations in blood pressure.

*ASCO Qualifying Statement. The use of systemic hormone therapy is not necessarily contraindicated in patients with other hormone-sensitive cancers like endometrial and ovarian cancer. Clinicians should discuss all options, including integrative approaches, with their patient, outlining the benefits and risks of each.*

### **CONDITION: GENITAL SYMPTOMS**

***Recommendation 6. The Expert Panel believes that for women with symptoms of vaginal and/or vulvar atrophy, such as dryness, the following stepwise approach should be followed:***

(continued on following page)

## THE BOTTOM LINE (CONTINUED)

***Lubricants for all sexual activity or touch, in addition to vaginal moisturizers to improve vulvovaginal tissue quality, may be tried first. It should be noted that moisturizers may need to be applied at a higher frequency (three to five times per week) in the vagina, at the vaginal opening, and on the external folds of the vulva for symptom relief in female patients with cancer and survivors.***<sup>151</sup>

For those who do not respond or whose symptoms are more severe at presentation, ***low-dose*** vaginal estrogen can be used. For women with hormone-positive breast cancer who are symptomatic and not responding to conservative measures, ***low-dose*** vaginal estrogen can be considered after a ***thorough*** discussion of risks and benefits.

***Lidocaine can also be offered for persistent introital pain and dyspareunia.***<sup>152</sup>

***For women with current or a history of breast cancer who are on aromatase inhibitors and have not responded to previous treatment, clinicians may offer vaginal dehydroepiandrosterone.***<sup>20-23</sup>

***Finally, clinicians may offer the selective estrogen receptor modulator ospemifene to postmenopausal women without current or a history of breast cancer who are experiencing dyspareunia, vaginal atrophy, or other vaginal pain.***<sup>24-26</sup>

***Clinicians should offer pain relievers to women on aromatase inhibitors who are experiencing arthralgia that interferes with intimacy.***

***Clinicians may suggest the use of skin protectants/sealants applied to the external folds of the vulva in women using pads for leakage and/or discharge.***

Vaginal dilators may be of benefit in the management of vaginismus and/or vaginal stenosis ***and can be offered to anyone having pain with examinations and/or sexual activity. This is particularly important for women treated with pelvic (or vaginal) radiation therapy. Ideally, benefit is greatest when started early and should not be recommended based on sexual activity or sexual orientation but, rather, to all women at risk for vaginal changes to be proactive in their sexual and vulvovaginal health.***

Cognitive behavioral therapy and ***pelvic floor (Kegel)*** exercises may be useful to decrease ***anxiety and discomfort and can*** lower urinary tract symptoms.

The Expert Panel believes that pelvic floor physiotherapy ***may be beneficial for patients experiencing symptoms of a potential pelvic floor dysfunction, including persistent pain and urinary and/or fecal leakage. Clinicians may refer patients to a urologist or urogynecologist for further evaluation and treatment of urinary incontinence or to a colorectal surgeon for fecal incontinence.***

*ASCO Qualifying Statement. There is limited supportive data on the use of vaginal dehydroepiandrosterone in women with a history of cancer or on endocrine therapy, so the risk/benefit for this population is not fully known. Ospemifene has not been evaluated in women with a history of cancer or on endocrine therapy, and therefore, the risk/benefit is not known for this population. A thorough discussion outlining the uncertainty should be had with the patient.*

#### ***For Men With Cancer***

#### **CONDITION: SEXUAL RESPONSE**

***Recommendation 1.*** It is recommended that phosphodiesterase type 5 inhibitor (PDE5i) medications be used to help men with erectile dysfunction.

Men who do not respond to PDE5i medications should consider alternate interventions, such as a vacuum erectile device (VED), medicated urethral system for erection, or intracavernosal injection.

There may be some benefit to initiating the use of any of the above interventions earlier after cancer treatment rather than later. ***Introduction prior to treatment initiation may be of benefit to some men.***

(continued on following page)

## THE BOTTOM LINE (CONTINUED)

***Surgical interventions, including penile prosthesis implantation for erectile dysfunction, can be offered to patients who are not responding to conventional medical therapy or reporting adverse effects with such therapy.***

***Clinicians may refer patients to a urologist for evaluation and treatment of stress urinary incontinence.***

*CCO Qualifying Statement.* The Expert Panel believes that men are best served by being offered a combination of psychosocial counseling with the aim of greater adaptation toward long-term use and PDE5i medication adherence together with PDE5i treatment. For men who are partnered, psychosocial counseling should be directed at the couple.

Men should be aware that it might take a long time for medications to work ***and that PDE5i medications might not work for all men, especially in those with preexisting comorbidities. Clinicians should discuss with patients the appropriate duration of use and alternative options (eg, surgery) if the medications fail to work satisfactorily.***

It is the opinion of the Expert Panel that any kind of regular stimulation (including masturbation) would likely be of benefit for improving sexual response, regardless of the stimulation used.

Contraindications include the use of nitrates in any form. Common acute adverse effects of PDE5i medications include headaches, flushing, dizziness, upset stomach, nasal congestion, and dyspepsia.

### **CONDITION: GENITAL CHANGES**

*Recommendation 2.* It is recommended that a VED be used daily to prevent penis length loss. There may be some benefit to initiating the use of VEDs earlier after cancer treatment rather than later. Early treatment with PDE5i medications may also be beneficial for this outcome.

### **CONDITION: INTIMACY/RELATIONSHIPS**

*Recommendation 3.* The Expert Panel believes that individual or couples counseling should be offered for those wishing to improve relationship or intimacy issues. Current evidence does not support a particular intervention to improve intimacy or relationships.

*ASCO Qualifying Statement.* The opportunity for partners to be involved should be offered rather than viewed as a necessary condition.

### **CONDITION: OVERALL SEXUAL FUNCTIONING AND SATISFACTION**

*Recommendation 4:* It is recommended that psychosocial counseling be offered to men with cancer (and partners) to potentially improve sexual functioning and satisfaction. It is also recommended that the use of pro-erectile agents and devices be considered, recognizing that most of the benefit is specifically for erectile dysfunction. ***With men who have sex with men, additional education may need to be provided on the changes in erection and alternative ways to maintain sexual intimacy.***

***Body image, including such issues as weight changes, disfigurement, scarring, and hair loss, should be discussed and normalized in men.***

***Clinicians should check testosterone levels, even if the patient has a cancer that is not typically associated with hormone changes. Options should be discussed when testosterone levels are within normal range but the patient or clinician feels supplementation can have a clinical benefit and is not contraindicated.***

*CCO Qualifying Statement.* Psychosocial counseling could be used to help couples integrate interventions into their usual sexual activities.

### **CONDITION: VASOMOTOR SYMPTOMS**

*Recommendation 5.* Men with vasomotor symptoms should be offered medication for symptomatic improvements. Options would include venlafaxine, medroxyprogesterone acetate, cyproterone acetate, and gabapentin. Acupuncture may be a suitable alternative, ***as may be other integrative medicine options, such as slow-breathing techniques and hypnosis, as evidence demonstrates clinical benefit in women.***

(continued on following page)

## THE BOTTOM LINE (CONTINUED)

***Psychosocial counseling (cognitive behavioral therapy) may provide a benefit and reduce vasomotor symptoms and should be offered.***

ASCO Qualifying Statement. Evidence supporting the clinical effectiveness of various integrative medicine techniques exists for women experiencing vasomotor symptoms.<sup>16-19</sup> The ASCO Expert Panel feels extrapolation to male patients is reasonable and an option for men suffering from vasomotor symptoms.

**Additional Resources**

More information, including a Data Supplement, a Methodology Supplement, slide sets, and clinical tools and resources, is available at [www.asco.org/survivorship-guidelines](http://www.asco.org/survivorship-guidelines) and [www.asco.org/guidelineswiki](http://www.asco.org/guidelineswiki). Patient information is available at [www.cancer.net](http://www.cancer.net).

A link to the guideline, Interventions to Address Sexual Problems in People With Cancer, can be found at <https://www.cancercareontario.ca/en/content/interventions-address-sexual-problems-people-cancer>

**ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients should have the opportunity to participate.**

Sexual health is an integral component of quality of life across the lifespan. Cancer survivors who experience sexual morbidity are at an increased risk of distress and poor quality of life. Impaired emotional well-being and quality of life in turn contribute to higher rates of morbidity and mortality among affected cancer survivors.<sup>5,6</sup> Sexual problems commonly include decreased desire, arousal disorders, pain (largely in women), and erectile dysfunction (in men). In addition to cultural and religious influences, sexual function is affected in a multifactorial way by one's overall health (the patient's and that of his/her partner), partner relationships, previous sexual history, medications, fatigue and stress, mood, view of sexual self, body image, incontinence, and hormonal changes. Cancer can independently affect sexual function by the nature of the disease and its treatment and/or result in changes to health, body image, or view of sexual self, and altered relationships secondary to illness.

There remains an overall reluctance from both clinicians and patients to talk about cancer- and treatment-related sexual difficulties.<sup>2,7,8</sup> Barriers from the clinician's perspective can include feeling inadequately trained or insufficiently skilled, limited awareness of effective interventions, lack of time, lack of privacy, and concerns about making patients feel uncomfortable.<sup>9</sup> Beyond these reasons, studies also suggest that clinicians may make assumptions based on factors such as age and presumed interest, overall prognosis, and whether the patient has a current partner.<sup>10</sup> For patients, barriers similarly may include concerns about making the doctor feel uncomfortable, embarrassment around the topic, belief that it is the clinician's responsibility to raise the issue, and that their sexual health concerns are not valid or are an expected and untreatable complication of their disease and its treatment.<sup>9,11-13</sup>

In 2016, Cancer Care Ontario (CCO) released guideline recommendations regarding interventions to improve sexual function in individuals with cancer. ASCO has established a process for endorsing and/or adapting other organizations' clinical practice guidelines. This article summarizes the results of that process and presents the adapted practice recommendations.

The original CCO recommendations appear in [Table 1](#) and online at <https://www.cancercareontario.ca/en/content/interventions-address-sexual-problems-people-cancer>.

#### OVERVIEW OF THE ASCO GUIDELINE ADAPTATION PROCESS

ASCO has policies and procedures for endorsing and/or adapting practice guidelines that have been developed by other professional organizations, with the goal of increasing the number of high-quality, ASCO-vetted guidelines available to the ASCO membership. The ASCO endorsement process involves an assessment by ASCO staff of candidate guidelines for methodological quality using the Rigor of Development subscale of the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument. (See Methodology Supplement for more details.) The CCO guideline for Interventions to Address Sexual Problems in People With Cancer rated highly on the AGREE II instrument and was identified as a potential candidate for endorsement by ASCO. During the endorsement process, modifications and qualifying statements were made by the ASCO Expert Panel ([Appendix Table A1](#), online only) to improve the guideline's applicability to the broader ASCO guideline audience. Due to the number and significance of these changes, the ASCO Clinical Practice Guidelines Committee leadership agreed that this product should be considered a guideline *adaptation*, and it was labeled as such going forward. All funding for the administration of the project was provided by ASCO.

#### Disclaimer

The clinical practice guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. ("ASCO") to assist providers in clinical decision-making. The information therein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new

**Table 1.** Original CCO and ASCO Adapted Recommendations and Qualifying Statements

CCO Recommendation	CCO Qualifying Statement	ASCO Adapted Recommendation	ASCO Qualifying Statement
<p>For all people with cancer</p> <p>Recommendation 1. It is recommended that there be a discussion with the patient, initiated by a member of the health care team, regarding sexual health and dysfunction resulting from the cancer or its treatment. Ideally, the conversation would include the patient's partner, if partnered. This issue should be raised at the time of diagnosis and continue to be reassessed periodically throughout follow-up.</p> <p>The Expert Panel believes that this is a vital recommendation. The recommendations that follow cannot be used unless someone has taken the initiative to ask.</p> <p>It is recommended that there be access to resources or referral information for the patient (and partner).</p>	<p>None</p>	<p>Recommendation 1. It is recommended that there be a discussion with the patient, initiated by a member of the health care team, regarding sexual health and dysfunction resulting from the cancer or its treatment. The conversation <b>could</b> include the patient's partner, <b>only if the patient so wishes</b>. This issue should be raised with the individual at the time of diagnosis and continue to be reassessed periodically throughout follow-up.</p> <p>The Expert Panel believes that this is a vital recommendation. The recommendations that follow cannot be used unless someone has taken the initiative to ask.</p> <p>It is recommended that there be access to resources or referral information for the patient (and partner).</p>	<p><b>ASCO Qualifying Statement. The Expert Panel believes that introduction of the topic of sexual function should be held with the patient alone, with the option of later partner inclusion if desired by the patient. Discussions should be congruent with the patient's literacy level, cultural/religious beliefs, and sexual orientation. This discussion should be offered at varied points of treatment and survivorship to assess or address any changes.</b></p>
<p>For women with cancer</p> <p>Sexual Response</p> <p>Recommendation 1. The Expert Panel believes that psychosocial counseling should be offered to women with cancer, aiming to improve elements of sexual response such as desire, arousal, or orgasm. Current evidence does not support one type of psychosexual education and counseling to be superior to another.</p> <p>No recommendation can be made for pharmacological interventions.</p> <p>Body image</p> <p>Recommendation 2. It is recommended that psychosocial counseling be offered to women with cancer and body image issues.</p> <p>If a woman is partnered, evidence indicates that couples-based interventions are effective when compared with usual care.</p> <p>No recommendation can be made for or against group therapy (with or without exercise) for women with body image issues.</p> <p>Intimacy/relationships</p> <p>Recommendation 3. It is recommended that psychosocial counseling be offered to women with cancer aiming to improve intimacy and relationship issues.</p> <p>If a woman is partnered, evidence indicates that couples-based interventions are effective when compared with usual care.</p>	<p>It is the opinion of the Expert Panel that any kind of regular stimulation (including masturbation) would likely be of benefit for improving sexual response, regardless of the stimulation.</p>	<p>Recommendation 1. The Expert Panel believes that psychosocial <b>and/or psychosexual</b> counseling should be offered to women with cancer, aiming to improve elements of sexual response such as desire, arousal, or orgasm. Current evidence does not support one type of psychosexual <b>or psychosexual</b> education and counseling to be superior to another.</p> <p><b>Clinicians may offer flibanserin to premenopausal women who are experiencing hypoactive sexual desire disorder.</b><sup>1,4,15</sup></p>	<p>It is the opinion of the Expert Panel that any kind of regular stimulation (including masturbation) would likely be of benefit for improving sexual response, regardless of the stimulation.</p> <p><b>ASCO Qualifying Statement. It should be noted that flibanserin has not been evaluated in women with a history of cancer or those on endocrine therapy. In addition, the risk/benefit ratio for this medication is uncertain.</b></p>
<p>None</p> <p>None</p> <p>None</p>	<p>Recommendation 2. It is recommended that psychosocial counseling be offered to women with cancer and body image issues.</p> <p>If a woman is partnered, evidence indicates that couples-based interventions are effective when compared with usual care.</p> <p>No recommendation can be made for or against group therapy (with or without exercise) for women with body image issues.</p>	<p>Recommendation 2. It is recommended that psychosocial counseling be offered to women with cancer and body image issues.</p> <p>If a woman is partnered, evidence indicates that couples-based interventions are effective when compared with usual care.</p> <p>No recommendation can be made for or against group therapy (with or without exercise) for women with body image issues.</p>	<p><b>ASCO Qualifying Statement. Clinicians should assess for body image issues early and often in the cancer care continuum and should take into account cultural and/or religious variations. Patients with preexisting depression and/or body image issues may be at a higher risk of susceptibility.</b></p>
<p>(continued on following page)</p>	<p>(continued on following page)</p>	<p>Recommendation 3. It is recommended that psychosocial counseling be offered to women with cancer aiming to improve intimacy and relationship issues.</p> <p>If a woman is partnered, evidence indicates that couples-based interventions are effective when compared with usual care.</p>	<p><b>ASCO Qualifying Statement. The Expert Panel views partner involvement in all cases to be the choice of the patient.</b></p>

Table 1. Original CCO and ASCO Adapted Recommendations and Qualifying Statements (continued)

CCO Recommendation	CCO Qualifying Statement	ASCO Adapted Recommendation	ASCO Qualifying Statement
<p>Overall sexual functioning and satisfaction</p> <p>Recommendation 4. The Expert Panel believes that psychosocial counseling directed at the individual or couple or delivered in a group be offered to women with cancer who have problems with overall sexual functioning. Physical exercise or pelvic floor physiotherapy, in addition to psychosocial counseling, may also be of benefit. Current evidence does not support a specific psychosocial counseling intervention to improve sexual functioning and satisfaction.</p>	None	<p>Recommendation 4. The Expert Panel believes that psychosocial counseling directed at the individual or couple or delivered in a group be offered to women with cancer who have problems with overall sexual functioning. Physical exercise or pelvic floor physiotherapy, in addition to psychosocial counseling, may also be of benefit. Current evidence does not support a specific psychosocial counseling intervention to improve sexual functioning and satisfaction.</p> <p><b>Health care providers should screen patients with cancer for overall sexual functioning and satisfaction, and a diagnosis should be established when there are physical issues playing a contributing role. All patients should be offered education and symptom management based on the patient's diagnosis. For patients having persistent concerns, such as physical issues, a gynecologic examination would be ideal. For those continuing to have relationship issues and/or distress, mental health counseling should be an option.</b></p>	<p><b>ASCO Qualifying Statement. The ASCO Expert Panel believes patients can still benefit if counseling is provided by licensed counselors available at the medical center even if specialized therapists (eg, sex therapists) are not available.</b></p>
Vasomotor symptoms	<p>Recommendation 5. For women with vasomotor symptoms, hormone therapy is the most effective intervention. For women unwilling or unable to use hormonal therapy, alternatives exist: for example, paroxetine, venlafaxine, gabapentin, or clonidine. Having a hormone-sensitive breast cancer is a contraindication to using systemic hormone therapy. Psychosocial counseling (cognitive behavioral therapy) may provide a benefit and reduce vasomotor symptoms and should be offered.</p>	<p>Recommendation 5. For women with vasomotor symptoms, hormone therapy is the most effective intervention. For women unwilling or unable to use hormonal therapy, alternatives exist: for example, paroxetine, venlafaxine, gabapentin, or clonidine. Having a hormone-sensitive breast cancer is a contraindication to using systemic hormone therapy. Psychosocial counseling (cognitive behavioral therapy) and/or clinical hypnosis may provide a benefit and reduce vasomotor symptoms and should be offered.<sup>16-19</sup></p>	<p><b>ASCO Qualifying Statement.</b> The Expert Panel emphasizes that women with non-hormone-sensitive cancers who develop vasomotor symptoms from their cancer treatment should be counseled to consider hormone therapy until the average age of menopause, approximately 51 years, at which point they should be re-evaluated. Risks typically cited for hormone therapy are derived from studies of postmenopausal women. Beyond the age of 51 years, hormone therapy is an individual therapy with few risks for symptomatic patients in their 50s. It should be intermittently evaluated for long-term use.</p> <p><b>The use of systemic hormone therapy is not necessarily contraindicated in patients with other hormone-sensitive cancers like endometrial and ovarian cancer. Clinicians should discuss all options, including integrative approaches, with their patient, outlining the benefits and risks of each.</b></p>
<p>When not contraindicated, estrogen therapy alone (oral, transdermal, or vaginal) is recommended for women who have had a hysterectomy, as it has a more beneficial risk/benefit profile. Paroxetine and fluoxetine should not be offered to women with breast cancer taking tamoxifen. Adverse events of clonidine include hypotension, light-headedness, headache, dry mouth, dizziness, sedation, and constipation. Sudden cessation can lead to significant elevations in blood pressure.</p>	<p>When not contraindicated, estrogen therapy alone (oral, transdermal, or vaginal) is recommended for women who have had a hysterectomy, as it has a more beneficial risk/benefit profile. Paroxetine and fluoxetine should not be offered to women with breast cancer taking tamoxifen. Adverse events of clonidine include hypotension, light-headedness, headache, dry mouth, dizziness, sedation, and constipation. Sudden cessation can lead to significant elevations in blood pressure.</p>	<p>When not contraindicated, estrogen therapy alone (oral, transdermal, or vaginal) is recommended for women who have had a hysterectomy, as it has a more beneficial risk/benefit profile. Paroxetine and fluoxetine should not be offered to women with breast cancer taking tamoxifen. Adverse events of clonidine include hypotension, light-headedness, headache, dry mouth, dizziness, sedation, and constipation. Sudden cessation can lead to significant elevations in blood pressure.</p>	<p>When not contraindicated, estrogen therapy alone (oral, transdermal, or vaginal) is recommended for women who have had a hysterectomy, as it has a more beneficial risk/benefit profile. Paroxetine and fluoxetine should not be offered to women with breast cancer taking tamoxifen. Adverse events of clonidine include hypotension, light-headedness, headache, dry mouth, dizziness, sedation, and constipation. Sudden cessation can lead to significant elevations in blood pressure.</p>

(continued on following page)

Table 1. Original CCO and ASCO Adapted Recommendations and Qualifying Statements (continued)

CCO Recommendation	CCO Qualifying Statement	ASCO Adapted Recommendation	ASCO Qualifying Statement
<p>Genital symptoms</p> <p>Recommendation 6. Women with symptoms of vaginal atrophy, such as vaginal dryness, should be managed in the same way as women without cancer. Vaginal moisturizers for daily comfort and/or lubricants with sexual activity may be tried. For those who do not respond or whose symptoms are more severe at presentation, vaginal estrogen can be safely used.</p> <p>Vaginal dilators may be of benefit in the management of vaginismus and/or vaginal stenosis.</p> <p>Cognitive behavioral therapy and exercise may be useful to decrease lower urinary tract symptoms.</p> <p>The Expert Panel believes that pelvic floor physiotherapy should also be offered to women with pain or other pelvic floor issues.</p>	<p>For women with hormone-positive breast cancer who are symptomatic and not responding to conservative measures, vaginal estrogen can be considered after a discussion.</p>	<p>Recommendation 6. <b>The Expert Panel believes that for women with symptoms of vaginal and/or vulvar atrophy, such as dryness, the following stepwise approach should be followed:</b></p> <p><b>Lubricants for all sexual activity or touch, in addition to vaginal moisturizers to improve vulvovaginal tissue quality, may be tried first. It should be noted that moisturizers may need to be applied at a higher frequency (three to five times per week) in the vagina, at the vaginal opening, and on the external folds of the vulva for symptom relief in female patients with cancer and survivors.<sup>151</sup></b></p> <p>For those who do not respond or whose symptoms are more severe at presentation, <b>low-dose</b> vaginal estrogen can be used. For women with hormone-positive breast cancer who are symptomatic and not responding to conservative measures, <b>low-dose</b> vaginal estrogen can be considered after a <b>thorough discussion of risks and benefits.</b></p> <p><b>Lidocaine can also be offered for persistent introital pain and dyspareunia.<sup>152</sup></b></p> <p><b>For women with current or a history of breast cancer who are on aromatase inhibitors and have not responded to previous treatment, clinicians may offer vaginal dehydroepiandrosterone.<sup>20-23</sup></b></p> <p><b>Finally, clinicians may offer the selective estrogen receptor modulator ospemifene to postmenopausal women without current or a history of breast cancer who are experiencing dyspareunia, vaginal atrophy, or other vaginal pain.<sup>24-26</sup></b></p> <p><b>Clinicians should offer pain relievers to women on aromatase inhibitors who are experiencing arthralgia that interferes with intimacy.</b></p> <p><b>Clinicians may suggest the use of skin protectants/sealants applied to the external folds of the vulva in women using pads for leakage and/or discharge.</b></p> <p>Vaginal dilators may be of benefit in the management of vaginismus and/or vaginal stenosis and can be offered to anyone having pain with examinations and/or sexual activity. <b>This is particularly important for women treated with pelvic (or vaginal) radiation therapy. Ideally, benefit is greatest when started early and should not be recommended based on sexual activity or sexual orientation but, rather, to all women at risk for vaginal changes to be proactive in their sexual and vulvovaginal health.</b></p> <p>Cognitive behavioral therapy and pelvic floor (Kegel) exercises may be useful to decrease anxiety and discomfort and can lower urinary tract symptoms.</p> <p>The Expert Panel believes that pelvic floor physiotherapy may be beneficial for patients experiencing symptoms of a potential pelvic floor dysfunction, including persistent pain and urinary and/or fecal leakage. Clinicians may refer patients to a urologist or urogynecologist for further evaluation and treatment of urinary incontinence or to a colorectal surgeon for fecal incontinence.</p>	<p><b>ASCO Qualifying Statement. There is limited supportive data on the use of vaginal dehydroepiandrosterone in women with a history of cancer or on endocrine therapy, so the risk/benefit for this population is not fully known.</b></p> <p><b>Ospemifene has not been evaluated in women with a history of cancer or on endocrine therapy, and therefore, the risk/benefit is not known for this population. A thorough discussion outlining the uncertainty should be had with the patient.</b></p>

(continued on following page)

Table 1. Original CCO and ASCO Adapted Recommendations and Qualifying Statements (continued)

CCO Recommendation	CCO Qualifying Statement	ASCO Adapted Recommendation	ASCO Qualifying Statement
<p>For men with cancer: Sexual response</p> <p>Recommendation 1. It is recommended that PDE5i medications be used to help men with erectile dysfunction.</p> <p>Men who do not respond to PDE5i medications should consider alternate interventions, such as a VED, urethral system for erection, or intracavernosal injection.</p> <p>There may be some benefit to initiating the use of any of the above interventions earlier after cancer treatment rather than later.</p>	<p>The Expert Panel believes that men are best served by being offered a combination of psychosocial counseling with the aim of greater adaptation toward long-term use and medication adherence together with PDE5i treatment. For men who are partnered, psychosocial counseling should be directed at the couple.</p> <p>Men should be aware that it might take a long time for medications to work.</p> <p>It is the opinion of the Expert Panel that any kind of regular stimulation (including masturbation) would likely be of benefit for improving sexual response, regardless of the stimulation used.</p> <p>Contraindications include the use of nitrates in any form. Common acute adverse effects of PDE5i medications include headaches, flushing, dizziness, upset stomach, nasal congestion, and dyspepsia.</p>	<p>Recommendation 1. It is recommended that PDE5i medications be used to help men with erectile dysfunction.</p> <p>Men who do not respond to PDE5i medications should consider alternate interventions, such as a VED, medicated urethral system for erection, or intracavernosal injection.</p> <p>There may be some benefit to initiating the use of any of the above interventions earlier after cancer treatment rather than later. <b>Introduction prior to treatment initiation may be of benefit to some men.</b></p> <p><b>Surgical interventions, including penile prosthesis implantation for erectile dysfunction, can be offered to patients who are not responding to conventional medical therapy or reporting adverse effects with such therapy.</b></p> <p><b>Clinicians may refer patients to a urologist for evaluation and treatment of stress urinary incontinence.</b></p>	<p><b>ASCO Qualifying Statement.</b> The Expert Panel believes that men are best served by being offered a combination of psychosocial counseling with the aim of greater adaptation toward long-term use and PDE5i medication adherence together with PDE5i treatment. For men who are partnered, psychosocial counseling should be directed at the couple.</p> <p>Men should be aware that it might take a long time for medications to work <b>and that PDE5i medications might not work for all men, especially in those with preexisting comorbidities. Clinicians should discuss with patients the appropriate duration of use and alternative options (eg, surgery) if the medications fail to work satisfactorily.</b></p> <p>It is the opinion of the Expert Panel that any kind of regular stimulation (including masturbation) would likely be of benefit for improving sexual response, regardless of the stimulation used.</p> <p>Contraindications include the use of nitrates in any form. Common acute adverse effects of PDE5i medications include headaches, flushing, dizziness, upset stomach, nasal congestion, and dyspepsia.</p>
<p>Genital changes</p> <p>Recommendation 2. It is recommended that a VED be used daily to prevent penis length loss. There may be some benefit to initiating the use of VEDs earlier after cancer treatment rather than later. Early treatment with PDE5i medications may also be beneficial for this outcome.</p>	<p>None</p>	<p>Recommendation 2. It is recommended that a VED be used daily to prevent penis length loss. There may be some benefit to initiating the use of VEDs earlier after cancer treatment rather than later. Early treatment with PDE5i medications may also be beneficial for this outcome.</p>	<p>None</p>
<p>Intimacy/relationships</p> <p>Recommendation 3. The Expert Panel believes that individual or couples counseling should be offered for those wishing to improve relationship or intimacy issues. Current evidence does not support a particular intervention to improve intimacy or relationships.</p>	<p>None</p>	<p>Recommendation 3. The Expert Panel believes that individual or couples counseling should be offered for those wishing to improve relationship or intimacy issues. Current evidence does not support a particular intervention to improve intimacy or relationships.</p>	<p><b>ASCO Qualifying Statement. The opportunity for partners to be involved should be offered rather than viewed as a necessary condition.</b></p>

(continued on following page)

**Table 1.** Original CCO and ASCO Adapted Recommendations and Qualifying Statements (continued)

CCO Recommendation	CCO Qualifying Statement	ASCO Adapted Recommendation	ASCO Qualifying Statement
<p>Overall sexual functioning and satisfaction</p> <p>Recommendation 4. It is recommended that psychosocial counseling be offered to men with cancer (and partners) to potentially improve sexual functioning and satisfaction. It is also recommended that the use of pro-erectile agents and devices be considered, recognizing that most of the benefit is specifically for erectile dysfunction.</p>	<p>Psychosocial counseling could be used to help couples integrate interventions into their usual sexual activities.</p>	<p>Recommendation 4. It is recommended that psychosocial counseling be offered to men with cancer (and partners) to potentially improve sexual functioning and satisfaction. It is also recommended that the use of pro-erectile agents and devices be considered, recognizing that most of the benefit is specifically for erectile dysfunction. <b>With men who have sex with men, additional education may need to be provided on the changes in erection and alternative ways to maintain sexual intimacy.</b></p> <p><b>Body image, including such issues as weight changes, disfigurement, scarring, and hair loss, should be discussed and normalized in men.</b></p> <p><b>Clinicians should check testosterone levels, even if the patient has a cancer that is not typically associated with hormone changes. Options should be discussed when testosterone levels are within normal range but the patient or clinician feels supplementation can have a clinical benefit and is not contraindicated.</b></p>	<p>Psychosocial counseling could be used to help couples integrate interventions into their usual sexual activities.</p>
<p>Vasomotor symptoms</p> <p>Recommendation 5. Men with vasomotor symptoms should be offered medication for symptomatic improvements. Options would include venlafaxine, medroxyprogesterone acetate, cyproterone acetate, and gabapentin. Acupuncture may be a suitable alternative.</p>	<p>None</p>	<p>Recommendation 5. Men with vasomotor symptoms should be offered medication for symptomatic improvements. Options would include venlafaxine, medroxyprogesterone acetate, cyproterone acetate, and gabapentin. Acupuncture may be a suitable alternative, <b>as may be other integrative medicine options, such as slow-breathing techniques and hypnosis, as evidence demonstrates clinical benefit in women.</b></p> <p><b>Psychosocial counseling (cognitive behavioral therapy) may provide a benefit and reduce vasomotor symptoms and should be offered.</b></p>	<p><b>ASCO Qualifying Statement. Evidence supporting the clinical effectiveness of various integrative medicine techniques exists for women experiencing vasomotor symptoms.<sup>16-19</sup> The ASCO Expert Panel feels extrapolation to male patients is reasonable and an option for men suffering from vasomotor symptoms.</b></p>

NOTE: Additional ASCO Expert Panel statements and edits to original CCO statements appear in **bold italics**. Abbreviations: CCO, Cancer Care Ontario; PDE5i, phosphodiesterase type 5 inhibitor; VED, vacuum erectile device.

evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations reflect high, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an “as is” basis, and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

### Guideline and Conflicts of Interest

The Expert Panel was assembled in accordance with ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines (“Policy,” found at <http://www.asco.org/rwc>). All members of the Expert Panel completed ASCO’s disclosure form, which requires disclosure of financial and other interests, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as a result of promulgation of the guideline. Categories for disclosure include employment; leadership; stock or other ownership; honoraria, consulting or advisory role; speaker’s bureau; research funding; patents, royalties, other intellectual property; expert testimony; travel, accommodations, expenses; and other relationships. In accordance with the Policy, the majority of the members of the Expert Panel did not disclose any relationships constituting a conflict under the Policy.

### CLINICAL QUESTION AND TARGET POPULATION

The guideline, Interventions to Address Sexual Problems in People With Cancer, addressed the effectiveness of pharmacological interventions, psychosocial counseling, or devices to manage sexual problems after cancer treatment in both men and women. The complete set of recommendations are provided in [Table 1](#).

The target population for the guideline, Interventions to Address Sexual Problems in People With Cancer, is adult ( $\geq 18$  years) men and women (and their partners) of all sexual orientations living with or surviving from cancer of any type. For the purposes of this guideline, men and women who were previously treated for a childhood cancer were not included. Although out of the scope of this guideline, the Expert Panel believes that adolescents (younger than 18) with cancer also require a tailored discussion

regarding sexual health and fertility, even if they are not yet sexually active. Further discussion of special issues affecting the adolescent and young adult population with cancer are found elsewhere.<sup>27,28</sup>

### SUMMARY OF THE CCO GUIDELINE DEVELOPMENT METHODOLOGY

The CCO guideline was developed by an author Expert Panel and a Scientific Advisory Panel that included experts in gynecology, urology, medical oncology, radiation oncology, psychology, psychiatry, behavioral sciences, supportive care, and sexual health. The literature search of Ovid MEDLINE, EMBASE, CINAHL, PsycINFO, and Cochrane Database was conducted on March 6, 2013. Owing to the lack of intervention studies identified, including patients with hematologic cancer, separate searches were also run on May 1, 2014, in the same databases. Details of the search strategies and the study inclusion criteria and outcomes of interest are available at <https://www.cancercareontario.ca/en/content/interventions-address-sexual-problems-people-cancer>.

The searches identified 103 studies for inclusion in the guideline’s qualitative synthesis of the literature. The CCO panel reviewed data from systematic reviews and primary studies covering sexual response, body image, intimacy and relationships, vasomotor symptoms, genital symptoms, and overall sexual function and satisfaction.

### RESULTS OF THE ASCO METHODOLOGY REVIEW

The methodology review of the guideline, Interventions to Address Sexual Problems in People With Cancer, was completed independently by two ASCO guideline staff members using the Rigor of Development subscale from the AGREE II instrument. The Rigor subscale consists of seven items that assess the quality of the processes used to gather and synthesize the relevant data and the methods used to formulate the guideline recommendations. Items such as the use of systematic methods in the search of the evidence, explicit links between the recommendations and the evidence, and consideration of benefits and risks were assessed. Each subscale item is rated on a seven-point scale from 1 (strongly disagree) to 7 (strongly agree). Detailed results of the scoring for this guideline are available upon request to [guidelines@asco.org](mailto:guidelines@asco.org). Overall, the guideline, Interventions to Address Sexual Problems in People With Cancer, itself scored 80%. There were some minor deficiencies with reporting on the methods for formulating the recommendations and on the strengths and limitations of the evidence considered (see Methodology Supplement at [www.asco.org/survivorship-guidelines](http://www.asco.org/survivorship-guidelines)).

The preliminary ASCO content reviewers of the Interventions to Address Sexual Problems in People With Cancer as well as the ASCO Expert Panel found the recommendations to be clear and thorough in the original guideline. Each section, including the guideline recommendations, the evidentiary base, and the development methods and external review process, was clear and well referenced from the systematic review.

This is the most recent information as of the publication date. For updates, the most recent information, and to submit new evidence, please visit [www.asco.org/survivorship-guidelines](http://www.asco.org/survivorship-guidelines) and the ASCO Guidelines Wiki ([www.asco.org/guidelineswiki](http://www.asco.org/guidelineswiki)).

## RESULTS OF THE ASCO CONTENT REVIEW

The ASCO Expert Panel reviewed the guideline, Interventions to Address Sexual Problems in People With Cancer, and concurs that the recommendations are clear, thorough, and based on the most relevant scientific evidence in this content area and present options that will be acceptable to patients. For the most part, the ASCO Expert Panel agrees with the recommendations as stated in the guideline, but modifications and further qualifications are made.

## METHODS AND RESULTS OF THE ASCO UPDATED LITERATURE REVIEW

This systematic review-based guideline product was developed by an Expert Panel with multidisciplinary, including patient, representation and by ASCO guidelines staff with health research

methodology experience. ASCO guidelines staff updated the Interventions to Address Sexual Problems in People With Cancer literature search. PubMed was searched up to April 3, 2017. The search was restricted to articles published in English. The updated search was guided by the “signals”<sup>29</sup> approach that is designed to identify only new, potentially practice-changing data—signals—that might translate into revised practice recommendations. The approach relies on targeted routine literature searching and the expertise of ASCO Expert Panel members to help identify potential signals. The Methodology Supplement (available at [www.asco.org/survivorship-guidelines](http://www.asco.org/survivorship-guidelines)) provides additional information about the signals approach.

The updated search yielded 159 records. A review of these results plus studies identified by searching reference lists and known seminal papers resulted in 19 new, recommendation-changing studies being included.<sup>14-18,20,22-26,30-36,152</sup> Table 2 summarizes the number and types of studies included per sexual dysfunction condition.

**Table 2.** Symptoms and Interventions for Sexual Dysfunction (adapted from CCO guideline)

Symptom	Possible Intervention	Evidence
<b>For women with cancer</b>		
Difficulty with sexual response, such as desire, arousal, or orgasm	Psychosocial counseling, psychosexual counseling Regular stimulation (including masturbation) Flibanerin for premenopausal women	Two systematic reviews <sup>14,15</sup> Two RCTs <sup>58,57</sup> Three other <sup>58-60</sup>
Body image	Psychosocial counseling, couples-based interventions	Two systematic reviews <sup>61,62</sup> Six RCTs <sup>56,57,63-66</sup> One other <sup>67</sup>
Intimacy/relationships	Psychosocial counseling, couples-based interventions	Zero systematic reviews Five RCTs <sup>56,57,63,64,68</sup> Three other <sup>59,60,67</sup>
Overall sexual functioning and satisfaction	Psychosocial counseling, education and symptom management, mental health counseling Physical exercise or pelvic floor physiotherapy	Four systematic reviews <sup>61,69-71</sup> Eleven RCTs <sup>57,63-66,68,72-76</sup> Five other <sup>59,60,67,77,78</sup>
Vasomotor symptoms	Psychosocial counseling (cognitive behavioral therapy) Paroxetine, fluoxetine (should not be offered to women with breast cancer taking tamoxifen), venlafaxine, gabapentin, or clonidine Integrative approaches, such as clinical hypnosis Estrogen therapy alone (oral, transdermal, or vaginal) when not contraindicated; hormone therapy (for women with non-hormone-sensitive cancers)	Three guidelines <sup>19,79,80</sup> One position statement <sup>19</sup> Zero systematic reviews Seven RCTs <sup>16-18,65,66,75,76</sup>
Genital symptoms, including dyspareunia, vaginal atrophy, or other vaginal pain	Cognitive behavioral therapy Exercise, pelvic floor physiotherapy Vaginal moisturizers, lubricants, vaginal estrogen, liquid sealants, vaginal dilators Selective estrogen receptor modulator ospemifene (for postmenopausal women without a current or history of breast cancer) Lidocaine dehydroepiandrosterone Pain relievers (for women on aromatase inhibitors)	Two guidelines <sup>79,81</sup> Three systematic reviews <sup>26,70,71</sup> Eleven RCTs <sup>20,22-25,65,66,72,75,82,152</sup> Four other <sup>78,83,84,151</sup>
<b>For men with cancer</b>		
Sexual response, including erectile dysfunction	PDE5i medications, VED, medicated urethral system, intracavernosal injection Surgical intervention, including penile and testicular prostheses Psychosocial counseling Regular stimulation (including masturbation)	Two systematic reviews <sup>85,86</sup> Twenty RCTs <sup>87-116</sup> Twenty-six other <sup>30-36,77,111-113,117-131</sup>
Genital changes, body image	VED PDE5i medications	Zero systematic reviews Two RCTs <sup>98,104</sup> One other <sup>114</sup>
Intimacy/relationships	Individual or couples counseling	One systematic review <sup>102,132</sup> Five RCTs <sup>102,103,110,133,134</sup> Three other <sup>116,135,136</sup>
Overall sexual functioning and satisfaction	Psychosocial counseling Pro-erectile agents and devices	Two systematic reviews <sup>132,137</sup> Six RCTs <sup>89,98,105,110,138,139</sup> Three other <sup>77,116,140</sup>
Vasomotor symptoms	Venlafaxine, medroxyprogesterone acetate, cyproterone acetate, and gabapentin Acupuncture, hypnosis Psychosocial counseling (cognitive behavioral therapy)	Seven RCTs <sup>16-18,115,141-143</sup> Seven other <sup>144-150</sup>

Abbreviations: CCO, Cancer Care Ontario; PDE5i, phosphodiesterase type 5 inhibitor; RCT, randomized controlled trial; VED, vacuum erectile device.

### Characteristics and Quality Assessment of Included Studies

Three systematic reviews,<sup>14,15,26</sup> nine randomized controlled trials (RCTs),<sup>16-18,20,22-25,152</sup> and seven observational studies<sup>30-36</sup> were identified and met the inclusion criteria for the updated literature review.

Two systematic reviews<sup>14,15</sup> collected RCT evidence and conducted meta-analyses to assess the efficacy and safety of flibanserin in the treatment of hypoactive sexual desire disorder in women. Three RCTs<sup>16-18</sup> investigated clinical hypnosis as a non-hormonal treatment of hot flashes in women. One systematic review with meta-analysis<sup>26</sup> and two RCTs<sup>24,25</sup> assessed the efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Three RCTs investigated intravaginal dehydroepiandrosterone on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and the genitourinary syndrome of menopause,<sup>20-22</sup> and one RCT considered lidocaine in breast cancer survivors with severe penetrative dyspareunia.<sup>152</sup> Finally, seven observational surgical studies investigated penile prosthesis for erectile dysfunction and testicular prosthesis for patients who have undergone orchiectomy for cancer of the testis.<sup>30-36</sup> While none of the studies were found to have serious methodological flaws that would raise concerns about the findings, the inherent limitations of surgical observational studies should be taken into consideration. Surgical studies tended to include a relatively small number of patients, and some studies only reported short follow-up times.<sup>30,31,33,36</sup>

### Outcomes of Included Studies

In 2015, the US Food and Drug Administration approved flibanserin as a treatment of hypoactive sexual desire disorder in premenopausal women.<sup>14</sup> Two systematic reviews with meta-analyses examined the effectiveness of flibanserin on primary outcomes, such as satisfying sexual events, sexual desire score, and female sexual function index.<sup>14,15</sup> Both found statistically significant effects in women randomized to flibanserin compared with those randomized to placebo. However, there also appeared to be a statistically significant increase in the risk of adverse effects such as dizziness, somnolence, nausea, and fatigue.

Three RCTs examined the effect of hypnosis<sup>16-18</sup> on reduction of vasomotor symptoms in postmenopausal women with or without a history of breast cancer. Each study found that hypnosis resulted in significant reductions in self-reported and physiologically measured hot flashes and hot flash scores in women. Additional benefits such as reduced anxiety and depression and improved sleep were also observed.<sup>17</sup>

One systematic review,<sup>26</sup> one pooled analysis of two RCTs,<sup>24</sup> and one additional RCT<sup>25</sup> investigated ospemifene, a selective estrogen receptor modulator, for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women. All studies found a statistically significant improvement in primary outcomes that included female sexual dysfunction, vaginal dryness, dyspareunia, and vaginal and/or vulvar irritation/itching compared with placebo.

Three RCTs investigating intravaginal dehydroepiandrosterone (prasterone) in postmenopausal women all showed improvements in the signs and symptoms of vaginal atrophy, including pain at sexual activity, vaginal dryness, vaginal pH, and arousal/sensation.<sup>20-23</sup>

Serum steroid levels appear to remain within normal postmenopausal values.<sup>20-23</sup>

In another RCT of 46 estrogen-deficient breast cancer survivors with severe penetrative dyspareunia, less pain during intercourse was reported with 4% aqueous lidocaine use compared with saline.<sup>152</sup> There was a statistically significant decrease in sexual distress (median score, 14; interquartile range, 3 to 20;  $P < .001$ ), and sexual function improved in all but one domain with lidocaine use. Of prior abstainers from intercourse who completed the study, 85% had resumed comfortable penetrative intimacy.<sup>152</sup>

Seven observational studies investigated penile prosthesis for erectile dysfunction and testicular prosthesis for patients who have undergone orchiectomy for cancer of the testis. Studies evaluating the efficacy, safety, and satisfaction with penile prosthesis implantation in men with various etiologies of erectile dysfunction, including consequence of radical prostatectomy and other pelvic surgery, vascular and metabolic syndrome, and spinal trauma, found the implants to be safe and efficacious with high patient and partner satisfaction.<sup>30-34</sup> While the surgical techniques and types of implants used differed in these studies, overall results appear to be consistent. Statistically and/or clinically significant improvements were found in the mean International Index of Erectile Function-5 (IIEF-5) scores,<sup>30,32,33</sup> Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) scores,<sup>30,31</sup> Erektion Harness Score,<sup>34</sup> and Global Assessment Questionnaire (GAQ) scores.<sup>34</sup>

High overall satisfaction with testicular implants is reported and ranges from 73% to 97%.<sup>35</sup> However, dissatisfaction with several particular attributes of the implants have been reported, namely the shape, consistency, size, and high intrascrotal position.<sup>35</sup> Acceptance rate appears to vary with age, such that the likelihood of accepting a prosthesis decreases with increasing age.<sup>35</sup> Psychological assessments measuring anxiety during sexual activity and desires and attempts to selectively avoid exposing one's body (or parts of one's body) to sexual partners (Body Exposure during Sexual Activities Questionnaire) showed statistically significant improvements with testicular implants ( $P < .001$ ).<sup>36</sup> Similarly, the Body-Esteem Scale, which measures self-confidence of each patient toward sexuality, also showed statistically significant improvements with the implants ( $P < .001$ ).<sup>36</sup> Interference with sexual activity, erectile functioning, or ejaculation was not observed.<sup>36</sup>

## DISCUSSION

The CCO recommendations were adapted by a multidisciplinary group of experts using evidence from the supplementary literature search and clinical experience as a guide. The majority of the recommendation text is listed verbatim from the guideline; however, there are some instances where the ASCO Expert Panel made modifications or additions to the recommendations for the broader ASCO audience and to reflect local context and updated empirical evidence. These changes are identified by **bold italics** in the Bottom Line Box and [Table 1](#) and discussed further below.

### Initiate at Each Visit

The Expert Panel strongly recommends designation of a specific treatment team member to query and discuss with each

patient any impact of cancer or cancer treatment on his/her sexuality. All patients should be provided with disease- and treatment-specific education and symptom management. Clinicians should initiate a discussion with the patient at the time of diagnosis and inquire about function periodically across treatment and into follow-up. For patients reporting problems in function, a diagnosis should be established when there are physical issues playing a contributing role. For women having persistent physical concerns, a gynecologic exam would be important. For women or men who disclose relationship difficulties and/or distress, referral for marital therapy should be available.

This guideline and its recommendations are patient focused, and inclusion of others, such as a partner, is the prerogative of the patient. It was acknowledged that psychosexual education is different from psychosocial education as sexual health and intimacy is often omitted in the latter conversations. Furthermore, clarification should be made about the difference between sex counseling and sex therapy. However, absence of a specialized sex therapist should not be a reason for lack of discussion. Patients can still benefit by counseling provided by available generic counselors who can help normalize the experience and increase support and guidance when a specialized sex therapist is not available. Ideally, education about the potential effect of cancer treatments on sexual function should be part of the informed consent process as well as any dialogue around plans for symptom management where therapies used themselves may affect sexual function (eg, pain medications, steroid use, antidepressants, etc). Discussions should be congruent with the patient's literacy level, cultural/religious beliefs, and sexual orientation.

## Resources

A key barrier to the delivery of optimal sexual care of patients with cancer and survivors is lack of awareness of whom or what may be available to address sexual problems or concerns when raised. Clinicians are encouraged to conduct a landscape review of key personnel and local resources to address sexual health within and proximate to their practice as a first step. Because these may change over time, an annual update of this list may be needed. The Expert Panel felt it equally important for clinicians to be made aware of high-quality national resources available for both patients (and their partners) and clinicians to help with education, assessment, and management of this distinct problem. The American Cancer Society ([www.cancer.org](http://www.cancer.org)) and the National Cancer Institute ([www.cancer.gov](http://www.cancer.gov)) both have comprehensive patient informational booklets about sex after cancer. International resources are also available and include the MacMillan Cancer Support Community in the United Kingdom ([www.macmillan.org.uk](http://www.macmillan.org.uk)), the Cancer Council of Australia ([www.cancercouncil.com.au](http://www.cancercouncil.com.au)), and the Scientific Network on Female Sexual Health and Cancer ([www.cancersexnetwork.org](http://www.cancersexnetwork.org)).<sup>9</sup>

Finding ways to ask about and assess sexual function is important. General screening tools include those from the National Comprehensive Cancer Network<sup>9</sup> and Patient-Reported Outcomes Measurement Information System (PROMIS-1) item screener.<sup>37</sup> Gender-specific tools include the Brief Sexual Symptom Checklist<sup>38</sup> (note: this scale has been adapted for use specifically in female patients with cancer<sup>9</sup>), Arizona Sexual Experience Scale (ASEX),<sup>39</sup>

and Female Sexual Function Index (FSFI) for women.<sup>40</sup> For men, the Sexual Health Inventory for Men (SHIM),<sup>41</sup> Sexual Quality of Life Male (SQoL-M),<sup>42</sup> and PROMIS are options. (Of note, FSFI and ASEX have been validated/used in cancer survivors; others have not.) Use of standardized, validated measures are recommended for screening and assessment. Consideration should be given to routine use of a simple screening measure in the clinical setting. This may help ensure that issues related to sexual health are identified and addressed; it can also help send a message to patients that addressing sexual problems is an important part of their cancer care.

Professional organizations also exist to help clinicians identify and facilitate connections with specialists in various areas of expertise. Sexual health counselors and therapists with expertise in treating cancer survivors can be located through the American Association of Sexuality Educators, Counselors, and Therapists or the Society for Sex Therapy and Research. Additional resources for men can be found at Sexual Medicine Society of North America ([www.sexhealthmatters.org](http://www.sexhealthmatters.org)). Resources specific for women include the International Society for the Study of Women's Sexual Health ([www.isswsh.org](http://www.isswsh.org)); The North American Menopause Society ([www.menopause.org](http://www.menopause.org)); the American Association of Sexuality Educators, Counselors and Therapists ([www.aasect.org](http://www.aasect.org)); and the Society for Sex Therapy and Research ([www.starnet.org](http://www.starnet.org)).

## Different Diagnoses Need Different Management

The ASCO Expert Panel noted the importance of broadly recognizing that different sexual problems will have different management strategies. It is important to consider both the physical as well as the psychosocial care appropriate for each of these. Furthermore, attention needs to be given to the fact that sexual satisfaction is not dependent on (and should not be narrowly defined as) the ability to engage in intercourse. Consideration should be given to the multiple ways of achieving sexual satisfaction for oneself, with or without a partner.

Across care, it is important to recognize that when adverse effects of treatment contribute to sexual dysfunction (eg, pain syndromes secondary to use of an aromatase inhibitor for women or erectile dysfunction secondary to hormonal therapy among men), this can lead to nonadherence or even discontinuation of cancer therapy. Providing information about and, as needed, relief from these (eg, pain medication for use with aromatase inhibitors) can improve sexual function. In general, improved symptom management leads to improved sexual response.<sup>43</sup>

Patients at high risk of cancer who choose to undergo cancer risk-reducing surgeries, such as bilateral mastectomy and/or oophorectomy, may also experience an effect on sexual functioning. Clinicians should be aware that while the target population of this guideline is people with cancer, the management strategies and support for patients undergoing prophylactic surgery should remain the same as outlined in this guideline.

## Overall Sexual Functioning and Satisfaction for Women Recommendation

The Expert Panel noted that current recommendations did not address the important role of symptom management and its effect on the sexual response. Improved symptom management

can be associated with improvement in the domains of the sexual response.<sup>44</sup> To this end, any underlying physical issue contributing to sexual dysfunction should be identified and managed.

### Sexual Response for Men Recommendations

Body image is important to men's sexual health. Issues such as weight change, increase in breast size, disfigurement, scarring, and hair loss should also be discussed and normalized in men. Normalizing these issues may help men reach a new comfort level with body image and functioning following their cancer.

In considering potential physical contributions to men's sexual function, clinicians should check testosterone levels, even if the patient has a cancer that is not typically associated with hormone changes. Options for potential supplementation should be discussed as indicated, including when testosterone levels are within normal range but the patient or clinician feels supplementation could have a clinical benefit and is not contraindicated.

Additional management options not covered in the CCO guideline warrant further discussion, including surgical interventions for erectile dysfunction. For patients refractory to medical therapy with oral phosphodiesterase type 5 inhibitors and intracavernosal vasoactive agents, penile prosthesis implant remains a relevant and desired option.<sup>45</sup> Indeed, penile implants have provided a predictable and reliable way for restoring erections in those patients for whom more-conservative measures have failed.<sup>46</sup> Available modern models have improved durability and operability and are less prone to wear.<sup>46</sup> As such, any patient with cancer in whom more conservative measures for erectile dysfunction have failed should be offered a discussion of the risks and benefits of prosthesis implantation surgery. Guidelines from the American Urological Association recommend that any patient considering prosthesis implantation should be informed of the types of prostheses available and made aware of possible adverse events, including infection, erosion, mechanical failure, and penile shortening.<sup>47</sup> Referral to urology is appropriate for these patients.

### HEALTH DISPARITIES

ASCO clinical practice guidelines represent expert recommendations on the best practices in disease management to provide the highest level of cancer care. However, many have limited access to health care. Racial and ethnic disparities in health care contribute significantly to this problem in the United States. Racial/ethnic minorities suffer disproportionately from comorbidities, experience more substantial obstacles to receiving care, are more likely to be uninsured, and are at greater risk of receiving care of poor quality than other Americans.<sup>48-51</sup> Many other patients lack access to care because of their geographic location and distance from appropriate treatment facilities. Awareness of these disparities in access to care should be considered in the context of this clinical practice guideline, and health care providers should strive to deliver the highest level of cancer care to these vulnerable populations.

Medically underserved populations may also suffer from low general literacy, low health literacy, and language and cultural

differences that can make assessment of sexual health a challenge.<sup>52</sup> In the general population, low socioeconomic status is associated with a higher prevalence of sexual problems, and evidence suggests that cancer survivors in medically underserved populations have high rates of sexual inactivity and sexual dysfunction.<sup>52</sup>

Sexual and gender minority populations are another diverse group at risk for receiving disparate care and suboptimal experiences with their health care journey.<sup>53</sup> While not well studied, some evidence suggests that predictors of sexual function after cancer do not differ by sexual orientation.<sup>10</sup> Regardless, sexual and gender minorities should have access to culturally sensitive and competent support services ([www.lgbtcancer.org](http://www.lgbtcancer.org)).

Ultimately, health care providers should strive to offer discussions and materials congruent with the survivor's literacy level, cultural or religious beliefs, and sexual orientation. It is paramount for ensuring optimum care for such vulnerable populations.

### ADDITIONAL RESOURCES

More information, including a Data Supplement with a reprint of all Interventions to Address Sexual Problems in People With Cancer guideline recommendations, a Methodology Supplement, slide sets, and clinical tools and resources, is available at [www.asco.org/survivorship-guidelines](http://www.asco.org/survivorship-guidelines) and [www.asco.org/guidelineswiki](http://www.asco.org/guidelineswiki). Patient information is available at [www.cancer.net](http://www.cancer.net). Visit [www.asco.org/guidelineswiki](http://www.asco.org/guidelineswiki) to provide comments on the guideline or to submit new evidence.

### Related ASCO Guidelines

- Fertility Guideline<sup>54</sup> (<http://ascopubs.org/doi/10.1200/jco.2013.49.2678>)
- Integration of Palliative Care Into Standard Oncology Practice<sup>55</sup> (<http://ascopubs.org/doi/10.1200/JCO.2016.70.1474>)
- Screening, Assessment, and Care of Anxiety and Depressive Symptoms<sup>5</sup> (<http://ascopubs.org/doi/10.1200/jco.2013.52.4611>)

### AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at [jco.org](http://jco.org).

### AUTHOR CONTRIBUTIONS

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

## REFERENCES

1. Jemal A, Ward EM, Johnson CJ, et al: Annual report to the nation on the status of cancer, 1975-2014, featuring survival. *J Natl Cancer Inst* 109:109, 2017
2. White ID: Sexual difficulties after pelvic radiotherapy: Improving clinical management. *Clin Oncol (R Coll Radiol)* 27:647-655, 2015
3. Zhou ES, Nekhlyudov L, Bober SL: The primary health care physician and the cancer patient: Tips and strategies for managing sexual health. *Transl Androl Urol* 4:218-231, 2015
4. Hendren SK, O'Connor BI, Liu M, et al: Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. *Ann Surg* 242:212-223, 2005
5. Andersen BL, DeRubeis RJ, Berman BS, et al: Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: An American Society of Clinical Oncology guideline adaptation. *J Clin Oncol* 32:1605-1619, 2014
6. Weaver KE, Forsythe LP, Reeve BB, et al: Mental and physical health-related quality of life among U.S. cancer survivors: Population estimates from the 2010 National Health Interview Survey. *Cancer Epidemiol Biomarkers Prev* 21:2108-2117, 2012
7. Flynn KE, Reese JB, Jeffery DD, et al: Patient experiences with communication about sex during and after treatment for cancer. *Psychooncology* 21:594-601, 2012
8. White ID, Faithfull S, Allan H: The reconstruction of women's sexual lives after pelvic radiotherapy: A critique of social constructionist and biomedical perspectives on the study of female sexuality after cancer treatment. *Soc Sci Med* 76:188-196, 2013
9. Bober SL, Reese JB, Barbera L, et al: How to ask and what to do: A guide for clinical inquiry and intervention regarding female sexual health after cancer. *Curr Opin Support Palliat Care* 10:44-54, 2016
10. Dizon DS, Suzin D, McIlvenna S: Sexual health as a survivorship issue for female cancer survivors. *Oncologist* 19:202-210, 2014
11. Stead ML, Brown JM, Fallowfield L, et al: Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. *Br J Cancer* 88:666-671, 2003
12. Hordern AJ, Street AF: Communicating about patient sexuality and intimacy after cancer: Mismatched expectations and unmet needs. *Med J Aust* 186:224-227, 2007
13. Forbat L, White I, Marshall-Lucette S, et al: Discussing the sexual consequences of treatment in radiotherapy and urology consultations with couples affected by prostate cancer. *BJU Int* 109:98-103, 2012
14. Jaspers L, Feys F, Bramer WM, et al: Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: A systematic review and meta-analysis. *JAMA Intern Med* 176:453-462, 2016
15. Gao Z, Yang D, Yu L, et al: Efficacy and safety of flibanserin in women with hypoactive sexual desire disorder: A systematic review and meta-analysis. *J Sex Med* 12:2095-2104, 2015
16. Barton DL, Schroeder KCF, Banerjee T, et al: Efficacy of a biobehavioral intervention for hot flashes: A randomized controlled pilot study. *Menopause* 24:774-782, 2017
17. Elkins G, Marcus J, Stearns V, et al: Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. *J Clin Oncol* 26:5022-5026, 2008
18. Elkins GR, Fisher WI, Johnson AK, et al: Clinical hypnosis in the treatment of postmenopausal hot flashes: A randomized controlled trial. *Menopause* 20:291-298, 2013
19. The North American Menopause Society: Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. *Menopause* 22:1155-1172, 2015
20. Labrie F, Archer DF, Koltun W, et al: Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. *Menopause* 23:243-256, 2016
21. Labrie F, Archer D, Bouchard C, et al: Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. *Menopause* 16:897-906, 2009
22. Labrie F, Archer D, Bouchard C, et al: Intravaginal dehydroepiandrosterone (prasterone), a physiological and highly efficient treatment of vaginal atrophy. *Menopause* 16:907-922, 2009
23. Labrie F, Archer D, Bouchard C, et al: Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. *Menopause* 16:923-931, 2009
24. Bruyniks N, Nappi RE, Castelo-Branco C, et al: Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. *Climacteric* 19:60-65, 2016
25. Constantine G, Graham S, Portman DJ, et al: Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: Results of a randomized, placebo-controlled trial. *Climacteric* 18:226-232, 2015
26. Cui Y, Zong H, Yan H, et al: The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: A systematic review and meta-analysis. *J Sex Med* 11:487-497, 2014
27. Morgan S, Davies S, Palmer S, et al: Sex, drugs, and rock 'n' roll: Caring for adolescents and young adults with cancer. *J Clin Oncol* 28:4825-4830, 2010
28. Levine J, Canada A, Stern CJ: Fertility preservation in adolescents and young adults with cancer. *J Clin Oncol* 28:4831-4841, 2010
29. Shojania KG, Sampson M, Ansari MT, et al: How quickly do systematic reviews go out of date? A survival analysis. *Ann Intern Med* 147:224-233, 2007
30. Antonini G, Busetto GM, De Berardinis E, et al: Minimally invasive infrapubic inflatable penile prosthesis implant for erectile dysfunction: Evaluation of efficacy, satisfaction profile and complications. *Int J Impot Res* 28:4-8, 2016
31. Gentile G, Franceschelli A, Massenio P, et al: Patient's satisfaction after 2-piece inflatable penile prosthesis implantation: An Italian multicentric study. *Arch Ital Urol Androl* 88:1-3, 2016
32. Egydio PH, Kuehling FE: Penile lengthening and widening without grafting according to a modified 'sliding' technique. *BJU Int* 116:965-972, 2015
33. Martínez-Salamanca JI, Espinós EL, Moncada I, et al: Management of end-stage erectile dysfunction and stress urinary incontinence after radical prostatectomy by simultaneous dual implantation using a single trans-scrotal incision: Surgical technique and outcomes. *Asian J Androl* 17:792-796, 2015
34. Yiu R, Binhas M: Combined implantation of a penile prosthesis and adjustable continence therapy ProACT in patients with erectile dysfunction and urinary incontinence after radical prostatectomy: Results of a prospective pilot study. *J Sex Med* 12:2481-2484, 2015
35. Dieckmann KP, Anheuser P, Schmidt S, et al: Testicular prostheses in patients with testicular cancer—acceptance rate and patient satisfaction. *BMC Urol* 15:16, 2015
36. Catanzariti F, Polito B, Polito M: Testicular prosthesis: Patient satisfaction and sexual dysfunctions in testis cancer survivors. *Arch Ital Urol Androl* 88:186-188, 2016
37. Flynn KE, Lindau ST, Lin L, et al: Development and validation of a single-item screener for self-reporting sexual problems in U.S. adults. *J Gen Intern Med* 30:1468-1475, 2015
38. Hatzichristou D, Rosen RC, Derogatis LR, et al: Recommendations for the clinical evaluation of men and women with sexual dysfunction. *J Sex Med* 7:337-348, 2010
39. McGahuey CA, Gelenberg AJ, Laukes CA, et al: The Arizona Sexual Experience Scale (ASEX): Reliability and validity. *J Sex Marital Ther* 26:25-40, 2000
40. Rosen R, Brown C, Heiman J, et al: The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. *J Sex Marital Ther* 26:191-208, 2000
41. Cappelleri JC, Rosen RC: The Sexual Health Inventory for Men (SHIM): A 5-year review of research and clinical experience. *Int J Impot Res* 17:307-319, 2005
42. Abraham L, Symonds T, Morris MF: Psychometric validation of a sexual quality of life questionnaire for use in men with premature ejaculation or erectile dysfunction. *J Sex Med* 5:595-601, 2008
43. DuHamel K, Schuler T, Nelson C, et al: The sexual health of female rectal and anal cancer survivors: Results of a pilot randomized psycho-educational intervention trial. *J Cancer Surviv* 10:553-563, 2016
44. Ganz PA, Greendale GA, Petersen L, et al: Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. *J Natl Cancer Inst* 92:1054-1064, 2000
45. Chung E: Penile prosthesis implant: Scientific advances and technological innovations over the last four decades. *Transl Androl Urol* 6:37-45, 2017
46. Mulcahy JJ: The development of modern penile implants. *Sex Med Rev* 4:177-189, 2016
47. Montague DK, Jarow JP, Broderick GA, et al: Chapter 1: The management of erectile dysfunction: An AUA update. *J Urol* 174:230-239, 2005
48. Howlader N, Noone AM, Krapcho M, et al: SEER cancer statistics review, 1975-2013, 2016. [http://seer.cancer.gov/csr/1975\\_2013](http://seer.cancer.gov/csr/1975_2013)
49. Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, The Commonwealth Fund, 2008
50. American Cancer Society: Cancer facts and figures for African Americans 2016-2018, 2016. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-facts-and-figures-for-african-americans/cancer-facts-and-figures-for-african-americans-2016-2018.pdf>
51. US Cancer Statistics Working Group: United States Cancer Statistics: 1999-2014. Cancer

Incidence and Mortality Data, 2017. <https://www.cdc.gov/uscs>

52. Bradford A, Fellman B, Urbauer D, et al: Assessment of sexual activity and dysfunction in medically underserved women with gynecologic cancers. *Gynecol Oncol* 139:134-140, 2015
53. Griggs J, Maingi S, Blinder V, et al: American Society of Clinical Oncology position statement: Strategies for reducing cancer health disparities among sexual and gender minority populations. *J Clin Oncol* 35:2203-2208, 2017
54. Loren AW, Mangu PB, Beck LN, et al: Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 31:2500-2510, 2013
55. Ferrell BR, Temel JS, Temin S, et al: Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 35:96-112, 2017
56. Kalaitzi C, Papadopoulos VP, Michas K, et al: Combined brief psychosexual intervention after mastectomy: Effects on sexuality, body image, and psychological well-being. *J Surg Oncol* 96:235-240, 2007
57. Jun EY, Kim S, Chang SB, et al: The effect of a sexual life reframing program on marital intimacy, body image, and sexual function among breast cancer survivors. *Cancer Nurs* 34:142-149, 2011
58. Mathias C, Cardeal Mendes CM, Pondé de Sena E, et al: An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer. *Ann Oncol* 17:1792-1796, 2006
59. Brotto LA, Erskine Y, Carey M, et al: A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. *Gynecol Oncol* 125:320-325, 2012
60. Schroder M, Mell LK, Hurteau JA, et al: Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. *Int J Radiat Oncol Biol Phys* 61:1078-1086, 2005
61. Hersch J, Juraskova I, Price M, et al: Psychosocial interventions and quality of life in gynecological cancer patients: A systematic review. *Psychooncology* 18:795-810, 2009
62. Scott JL, Kayser K: A review of couple-based interventions for enhancing women's sexual adjustment and body image after cancer. *Cancer J* 15:48-56, 2009
63. Baucom DH, Porter LS, Kirby JS, et al: A couple-based intervention for female breast cancer. *Psychooncology* 18:276-283, 2009
64. Sharif F, Abshorshori N, Tahmasebi S, et al: The effect of peer-led education on the life quality of mastectomy patients referred to breast cancer-clinics in Shiraz, Iran 2009. *Health Qual Life Outcomes* 8:74, 2010
65. Duijts SF, van Beurden M, Oldenburg HS, et al: Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: Results of a randomized, controlled, multicenter trial. *J Clin Oncol* 30:4124-4133, 2012
66. Yang EJ, Lim JY, Rah UW, et al: Effect of a pelvic floor muscle training program on gynecologic cancer survivors with pelvic floor dysfunction: A randomized controlled trial. *Gynecol Oncol* 125:705-711, 2012
67. Decker CL, Pais S, Miller KD, et al: A brief intervention to minimize psychosexual morbidity in dyads coping with breast cancer. *Oncol Nurs Forum* 39:176-185, 2012
68. Classen CC, Chivers ML, Urowitz S, et al: Psychosexual distress in women with gynecologic cancer: A feasibility study of an online support group. *Psychooncology* 22:930-935, 2013
69. Taylor S, Harley C, Ziegler L, et al: Interventions for sexual problems following treatment for breast cancer: A systematic review. *Breast Cancer Res Treat* 130:711-724, 2011
70. Miles T, Johnson N: Vaginal dilator therapy for women receiving pelvic radiotherapy. *Cochrane Database Syst Rev* (9):CD007291, 2010
71. Johnson N, Miles TP, Cornes P: Dilating the vagina to prevent damage from radiotherapy: Systematic review of the literature. *BJOG* 117:522-531, 2010
72. Rowland JH, Meyerowitz BE, Crespi CM, et al: Addressing intimacy and partner communication after breast cancer: A randomized controlled group intervention. *Breast Cancer Res Treat* 118:99-111, 2009
73. Marcus AC, Garrett KM, Cella D, et al: Can telephone counseling post-treatment improve psychosocial outcomes among early stage breast cancer survivors? *Psychooncology* 19:923-932, 2010
74. Schover LR, Yuan Y, Fellman BM, et al: Efficacy trial of an Internet-based intervention for cancer-related female sexual dysfunction. *J Natl Compr Canc Netw* 11:1389-1397, 2013
75. Sisonodi P, Kimmig R, Kubista E, et al: Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients—data from LIBERATE trial. *Maturitas* 70:365-372, 2011
76. Schover LR, Rhodes MM, Baum G, et al: Sisters Peer Counseling in Reproductive Issues After Treatment (SPIRIT): A peer counseling program to improve reproductive health among African American breast cancer survivors. *Cancer* 117:4983-4992, 2011
77. Ayaz S, Kubilay G: Effectiveness of the PLISSIT model for solving the sexual problems of patients with stoma. *J Clin Nurs* 18:89-98, 2009
78. Juraskova I, Jarvis S, Mok K, et al: The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. *J Sex Med* 10:2549-2558, 2013
79. Reid R, Abramson BL, Blake J, et al: Managing menopause. *J Obstet Gynaecol Can* 36:830-833, 2014
80. North American Menopause Society: The 2012 hormone therapy position statement of: The North American Menopause Society. *Menopause* 19:257-271, 2012
81. The North American Menopause Society: Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. *Menopause* 20:888-902, 2013
82. Lee YK, Chung HH, Kim JW, et al: Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: A randomized controlled trial. *Obstet Gynecol* 117:922-927, 2011
83. Law E, Kelvin JF, Thom B, et al: Prospective study of vaginal dilator use adherence and efficacy following radiotherapy. *Radiother Oncol* 116:149-155, 2015
84. Witherby S, Johnson J, Demers L, et al: Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: A phase I/II study. *Oncologist* 16:424-431, 2011
85. Candy B, Jones L, Vickerstaff V, et al: Interventions for sexual dysfunction following treatments for cancer in women. *Cochrane Database Syst Rev* 2:CD005540, 2016
86. Montorsi F, McCullough A: Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: A systematic review of clinical data. *J Sex Med* 2:658-667, 2005
87. Park SY, Choi GS, Park JS, et al: Efficacy and safety of udenafil for the treatment of erectile dysfunction after total mesorectal excision of rectal cancer: A randomized, double-blind, placebo-controlled trial. *Surgery* 157:64-71, 2015
88. Ilic D, Hindson B, Duchesne G, et al: A randomized, double-blind, placebo-controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. *J Med Imaging Radiat Oncol* 57:81-88, 2013
89. Watkins Bruner D, James JL, Bryan CJ, et al: Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: Results of RTOG 0215. *J Sex Med* 8:1228-1238, 2011
90. Incrocci L, Hop WC, Slob AK: Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer. *Urology* 62:116-120, 2003
91. Incrocci L, Slagter C, Slob AK, et al: A randomized, double-blind, placebo-controlled, crossover study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. *Int J Radiat Oncol Biol Phys* 66:439-444, 2006
92. Incrocci L, Slob AK, Hop WC: Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: An open-label extension of a blinded trial. *Urology* 70:1190-1193, 2007
93. Harrington C, Campbell G, Wynne C, et al: Randomised, placebo-controlled, crossover trial of sildenafil citrate in the treatment of erectile dysfunction following external beam radiation treatment of prostate cancer. *J Med Imaging Radiat Oncol* 54:224-228, 2010
94. Pace G, Del Rosso A, Vicentini C: Penile rehabilitation therapy following radical prostatectomy. *Disabil Rehabil* 32:1204-1208, 2010
95. Bannowsky A, Schulze H, van der Horst C, et al: Recovery of erectile function after nerve-sparing radical prostatectomy: Improvement with nightly low-dose sildenafil. *BJU Int* 101:1279-1283, 2008
96. Mosbah A, El Bahnasawy M, Osman Y, et al: Early versus late rehabilitation of erectile function after nerve-sparing radical cystoprostatectomy: A prospective randomized study. *J Sex Med* 8:2106-2111, 2011
97. McCullough AR, Levine LA, Padma-Nathan H: Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate: Sub-analysis of a longitudinal randomized double-blind placebo-controlled trial. *J Sex Med* 5:476-484, 2008
98. Montorsi F, Brock G, Stolzenburg JU, et al: Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: A randomized placebo-controlled study (REACTT). *Eur Urol* 65:587-596, 2014
99. Ricardi U, Gontero P, Ciammella P, et al: Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer

men: A randomized phase II trial. *J Sex Med* 7: 2851-2859, 2010

**100.** Pavlovich CP, Levinson AW, Su LM, et al: Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: Results of a randomized double-blind trial with placebo. *BJU Int* 112:844-851, 2013

**101.** Montorsi F, Brock G, Lee J, et al: Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. *Eur Urol* 54:924-931, 2008

**102.** Canada AL, Neese LE, Sui D, et al: Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. *Cancer* 104:2689-2700, 2005

**103.** Schover LR, Canada AL, Yuan Y, et al: A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. *Cancer* 118:500-509, 2012

**104.** Köhler TS, Pedro R, Hendlin K, et al: A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. *BJU Int* 100: 858-862, 2007

**105.** Zelefsky MJ, Shasha D, Branco RD, et al: Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer. *J Urol* 192:868-874, 2014

**106.** Engel JD: Effect on sexual function of a vacuum erection device post-prostatectomy. *Can J Urol* 18:5721-5725, 2011

**107.** Lin YH, Yu TJ, Lin VC, et al: Effects of early pelvic-floor muscle exercise for sexual dysfunction in radical prostatectomy recipients. *Cancer Nurs* 35: 106-114, 2012

**108.** Titta M, Tavolini IM, Dal Moro F, et al: Sexual counseling improved erectile rehabilitation after non-nerve-sparing radical retropubic prostatectomy or cystectomy—results of a randomized prospective study. *J Sex Med* 3:267-273, 2006

**109.** Cormie P, Newton RU, Taaffe DR, et al: Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: A randomized controlled trial. *Prostate Cancer Prostatic Dis* 16:170-175, 2013

**110.** Hanisch LJ, Bryan CJ, James JL, et al: Impact of sildenafil on marital and sexual adjustment in patients and their wives after radiotherapy and short-term androgen suppression for prostate cancer: Analysis of RTOG 0215. *Support Care Cancer* 20: 2845-2850, 2012

**111.** Nishizawa Y, Ito M, Saito N, et al: Male sexual dysfunction after rectal cancer surgery. *Int J Colorectal Dis* 26:1541-1548, 2011

**112.** Salonia A, Gallina A, Zanni G, et al: Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. *Eur Urol* 53:564-570, 2008

**113.** Reese JB, Porter LS, Somers TJ, et al: Pilot feasibility study of a telephone-based couples intervention for physical intimacy and sexual concerns in colorectal cancer. *J Sex Marital Ther* 38:402-417, 2012

**114.** Dalkin BL, Christopher BA: Preservation of penile length after radical prostatectomy: Early intervention with a vacuum erection device. *Int J Impot Res* 19:501-504, 2007

**115.** Irani J, Salomon L, Oba R, et al: Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flashes in men taking gonadotropin-releasing

hormone analogues for prostate cancer: A double-blind, randomised trial. *Lancet Oncol* 11:147-154, 2010

**116.** Ramsawh HJ, Morgentaler A, Covino N, et al: Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy. *J Urol* 174:1395-1398, 2005

**117.** Pahlajani G, Raina R, Jones JS, et al: Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function. *BJU Int* 106:1524-1527, 2010

**118.** Pugh TJ, Mahmood U, Swanson DA, et al: Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. *Brachytherapy* 14:160-165, 2015

**119.** Fujioka H, Ishimura T, Sakai Y, et al: Erectile function after brachytherapy with external beam radiation for prostate cancer. *Arch Androl* 50:295-301, 2004

**120.** Ogura K, Ichioka K, Terada N, et al: Role of sildenafil citrate in treatment of erectile dysfunction after radical retropubic prostatectomy. *Int J Urol* 11: 159-163, 2004

**121.** Schiff JD, Bar-Chama N, Cesaretti J, et al: Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. *BJU Int* 98:1255-1258, 2006

**122.** Mulhall JP, Parker M, Waters BW, et al: The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. *BJU Int* 105:37-41, 2010

**123.** Megas G, Papadopoulos G, Stathouros G, et al: Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction. *BJU Int* 112:E169-E176, 2013

**124.** Menard J, Tremieux JC, Faix A, et al: Erectile function and sexual satisfaction before and after penile prosthesis implantation in radical prostatectomy patients: A comparison with patients with vasculogenic erectile dysfunction. *J Sex Med* 8: 3479-3486, 2011

**125.** Mydlo JH, Viterbo R, Crispin P: Use of combined intracorporeal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. *BJU Int* 95:843-846, 2005

**126.** Natali A, Masieri L, Lanciotti M, et al: A comparison of different oral therapies versus no treatment for erectile dysfunction in 196 radical nerve-sparing radical prostatectomy patients. *Int J Impot Res* 27:1-5, 2015

**127.** Ohebshalom M, Parker M, Guhring P, et al: The efficacy of sildenafil citrate following radiation therapy for prostate cancer: Temporal considerations. *J Urol* 174:258-262, 2005

**128.** Raina R, Agarwal A, Allamaneni SS, et al: Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. *Urology* 65: 360-364, 2005

**129.** Raina R, Agarwal A, Goyal KK, et al: Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. *Urology* 62: 1103-1108, 2003

**130.** Raina R, Pahlajani G, Agarwal A, et al: The early use of tamsulosin after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. *BJU Int* 100:1317-1321, 2007

**131.** Balbontin FG, Moreno SA, Bley E, et al: Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. *BJU Int* 114:125-130, 2014

**132.** Chisholm KE, McCabe MP, Wootten AC, et al: Review: Psychosocial interventions addressing sexual or relationship functioning in men with prostate cancer. *J Sex Med* 9:1246-1260, 2012

**133.** Porter LS, Keefe FJ, Baucom DH, et al: Partner-assisted emotional disclosure for patients with gastrointestinal cancer: Results from a randomized controlled trial. *Cancer* 115: 4326-4338, 2009 (suppl 18)

**134.** Porter LS, Keefe FJ, Baucom DH, et al: Partner-assisted emotional disclosure for patients with GI cancer: 8-week follow-up and processes associated with change. *Support Care Cancer* 20: 1755-1762, 2012

**135.** Chambers SK, Schover L, Halford K, et al: ProsCan for Couples: A feasibility study for evaluating peer support within a controlled research design. *Psychooncology* 22:475-479, 2013

**136.** Collins AL, Love AW, Bloch S, et al: Cognitive existential couple therapy for newly diagnosed prostate cancer patients and their partners: A descriptive pilot study. *Psychooncology* 22:465-469, 2013

**137.** Lassen B, Gattinger H, Saxer S: A systematic review of physical impairments following radical prostatectomy: Effect of psychoeducational interventions. *J Adv Nurs* 69:2602-2612, 2013

**138.** Molton IR, Siegel SD, Penedo FJ, et al: Promoting recovery of sexual functioning after radical prostatectomy with group-based stress management: The role of interpersonal sensitivity. *J Psychosom Res* 64:527-536, 2008

**139.** Siddons HM, Wootten AC, Costello AJ: A randomised, wait-list controlled trial: Evaluation of a cognitive-behavioural group intervention on psychosexual adjustment for men with localised prostate cancer. *Psychooncology* 22:2186-2192, 2013

**140.** Lee IH, Sadetsky N, Carroll PR, et al: The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors. *J Urol* 179:1072-1076, 2008; discussion 1076

**141.** Vitols MZ, Griffin L, Tomlinson WV, et al: Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. *J Clin Oncol* 31: 4092-4098, 2013

**142.** Loprinzi CL, Dueck AC, Khojraty BS, et al: A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). *Ann Oncol* 20:542-549, 2009

**143.** Frisk J, Spetz AC, Hjertberg H, et al: Two modes of acupuncture as a treatment for hot flashes in men with prostate cancer—a prospective multicenter study with long-term follow-up. *Eur Urol* 55: 156-163, 2009

**144.** Moraska AR, Atherton PJ, Szydio DW, et al: Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation Study-NCCTG Trial N00CB. *J Support Oncol* 8: 128-132, 2010

**145.** Ashamalla H, Jiang ML, Guirguis A, et al: Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy. *Int J Radiat Oncol Biol Phys* 79:1358-1363, 2011

**146.** Beer TM, Benavides M, Emmons SL, et al: Acupuncture for hot flashes in patients with prostate cancer. *Urology* 76:1182-1188, 2010

**147.** Harding C, Harris A, Chadwick D: Auricular acupuncture: A novel treatment for vasomotor symptoms associated with luteinizing-hormone

releasing hormone agonist treatment for prostate cancer. *BJU Int* 103:186-190, 2009

148. Loprinzi CL, Barton DL, Carpenter LA, et al: Pilot evaluation of paroxetine for treating hot flashes in men. *Mayo Clin Proc* 79:1247-1251, 2004

149. Naoe M, Ogawa Y, Shichijo T, et al: Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under

androgen-deprivation therapy for prostate cancer. *Prostate Cancer Prostatic Dis* 9:275-278, 2006

150. Vandecasteele K, Ost P, Oosterlinck W, et al: Evaluation of the efficacy and safety of *Salvia officinalis* in controlling hot flashes in prostate cancer patients treated with androgen deprivation. *Phytother Res* 26:208-213, 2012

151. Carter J, Stabile C, Seidel B, et al: Vaginal and sexual health treatment strategies within a female sexual medicine program for cancer patients and survivors. *J Cancer Surviv* 11:274-283, 2017

152. Goetsch MF, Lim JY, Caughey AB: A practical solution for dyspareunia in breast cancer survivors: A randomized controlled trial. *J Clin Oncol* 33:3394-3400, 2015

### Affiliations

Jeanne Carter, Katherine DuHamel, and Shari Goldfarb, Memorial Sloan Kettering Cancer Center, New York; Michael A. Diefenbach, Northwell Health, Manhasset, NY; Christina Lacchetti, American Society of Clinical Oncology, Alexandria; Sage Bolte, Inova, Fairfax, VA; Barbara L. Andersen, Ohio State University, Columbus, OH; Debra L. Barton, University of Michigan, Ann Arbor, MI; Shari Damast, Yale School of Medicine, New Haven, CT; Judith Florendo, Florendo Physical Therapy, Chicago; Sigrun Hallmeyer, Oncology Specialists SC, Park Ridge, IL; Patricia A. Ganz, University of California, Los Angeles, CA; David M. Kushner, University of Wisconsin, Madison, WI; and Julia H. Rowland, National Cancer Institute, Bethesda, MD.

## Listen to Cancer Stories: A New JCO Podcast Series

These JCO podcasts, called **Cancer Stories: The Art of Oncology**, feature a dramatic reading of an Art of Oncology article performed by a celebrity actor or artist, followed by a Q&A session with the author of the article.

- "Talking to Children With Cancer: Sometimes Less Is More," written by David N. Korones, MD, and read by Jason George from the television show *Grey's Anatomy*, a doctor struggles to convey a prognosis to his cancer patient.
- "White Knuckling," written by Daniel Rayson, MD, and read by Peri Gilpin from the television show *Frasier*, is a tale of two nurses—one who has cancer, and one who is her caregiver.
- "Haunted," written by Katherine E. Reeder-Hayes, MD, MBA, MS, and read by JoBeth Williams from the films *Poltergeist*, *Kramer vs. Kramer*, and *The Big Chill*, a doctor recalls how patients who have passed away both haunt and encourage her.

Listen to these and other Cancer Stories today! Visit the Special Content section at [JCO.org](http://JCO.org)

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

**Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/jco/site/ife](http://ascopubs.org/jco/site/ife).

**Jeanne Carter**

No relationship to disclose

**Christina Lacchetti**

No relationship to disclose

**Barbara L. Andersen**

No relationship to disclose

**Debra L. Barton**

**Research Funding:** Merck Foundation

**Sage Bolte**

No relationship to disclose

**Shari Damast**

No relationship to disclose

**Michael A. Diefenbach**

No relationship to disclose

**Katherine DuHamel**

No relationship to disclose

**Judith Florendo**

No relationship to disclose

**Patricia A. Ganz**

**Leadership:** Intrinsic LifeSciences (I)

**Stock or Other Ownership:** Xenon Pharmaceuticals (I), Intrinsic LifeSciences (I), Silarus Therapeutics (I), Merganser Biotech (I), TEVA Pharmaceuticals Industries, Novartis, Merck, Johnson & Johnson, Pfizer, GlaxoSmithKline, Abbott Laboratories

**Honoraria:** Biogen (I)

**Consulting or Advisory Role:** Keryx Biopharmaceuticals (I), Merganser Biotech (I), Silarus Therapeutics (I), InformedDNA, Vifor Pharma (I), Eli Lilly

**Speakers' Bureau:** La Jolla Pharmaceutical Company (I)

**Research Funding:** Keryx Biopharmaceuticals (I)

**Patents, Royalties, Other Intellectual Property:** Related to iron metabolism and the anemia of chronic disease (I), Up-to-Date royalties for section editor on survivorship

**Travel, Accommodations, Expenses:** Intrinsic LifeSciences (I), Keryx Biopharmaceuticals (I)

**Shari Goldfarb**

**Consulting or Advisory Role:** Sermonix Pharmaceuticals, AMAG Pharmaceuticals, Procter & Gamble, Adgero Biopharmaceuticals

**Research Funding:** Paxman, Valeant Pharmaceuticals International

**Sigrun Hallmeyer**

**Employment:** Oncology Specialists SC, Advocate Medical Group

**Leadership:** Oncology Specialists SC, Advocate Lutheran General Hospital

**Honoraria:** Bristol-Myers Squibb, Pfizer

**Consulting or Advisory Role:** Cardinal Health, Bristol-Myers Squibb, KBL Biologics

**Speakers' Bureau:** Bristol-Myers Squibb, Pfizer

**Research Funding:** Russell Research Institute (Inst)

**Travel, Accommodations, Expenses:** Bristol-Myers Squibb, Cardinal Health

**David M. Kushner**

No relationship to disclose

**Julia H. Rowland**

No relationship to disclose

**Acknowledgment**

The Expert Panel thanks Tara Henderson and Eric Singer and the Clinical Practice Guidelines Committee for their thoughtful reviews and insightful comments on this guideline adaptation.

**Appendix**

**Table A1.** Interventions to Address Sexual Problems in People With Cancer: ASCO Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline Expert Panel Membership

Name	Affiliation
Julia H. Rowland, PhD, co-chair Developmental Psychology	National Cancer Institute
Jeanne Carter, PhD, co-chair Clinical Psychology	Memorial Sloan Kettering Cancer Center
Barbara L. Andersen, PhD Clinical Psychology	Ohio State University
Debra L. Barton, PhD Nursing	University of Michigan
Shari Damast, MD Radiation Oncology	Yale School of Medicine
Michael A. Diefenbach, PhD Behavioral Science	Northwell Health
Katherine DuHamel, PhD Clinical Psychology	Memorial Sloan Kettering Cancer Center
Judith Florendo, DPT Physical Therapy	Florendo Physical Therapy
Patricia A. Ganz, MD Breast Medical Oncology	University of California
Shari Goldfarb, MD Breast Medical Oncology	Memorial Sloan Kettering Cancer Center
David M. Kushner, MD Gynecologic Oncology	University of Wisconsin
Sigrun Hallmeyer, MD Medical Oncology, Practice Guidelines Implementation Network Representative	Oncology Specialists SC
Sage Bolte, PhD Patient Representative	Inova
Christina Lacchetti Staff/Health Research Methodologist	American Society of Clinical Oncology